================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
SETTLEMENT IN CIVIL LAW SUITS IN UNITED STATES
BY OPT-OUT PLAINTIFFS REGARDING METHIONINE
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 19, 2002
-----------------
Commission File Number
-------------------
MITSUI & CO., LTD.
-------------------------------------------------------
(Translation of registrant's name into English)
2-1, OHTEMACHI 1-CHOME CHIYODA-KU, TOKYO 100-0004 JAPAN
-------------------------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F X Form 40-F
------ ------
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
-------
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
-------
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant's "home country"), or under the rules of the home
country exchange on which the registrant's securities are traded, as long as the
report or other document is not a press release, is not required to be and has
not been distributed to the registrant's security holders, and, if discussing a
material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
------ -------
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
-------
================================================================================
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: November 19, 2002
MITSUI & CO., LTD.
By: /s/ Tasuku Kondo
----------------------------------------
Name: Tasuku Kondo
Title: Executive Director
Senior Executive Managing Officer
Chief Financial Officer
November 19, 2002
To: the Press
Re: Settlement in Civil Law Suits in United States
by Opt-Out Plaintiffs Regarding Methionine
Mitsui & Co., Ltd. ("Mitsui Japan"), Mitsui & Co. (U.S.A.), Inc. ("Mitsui USA")
and Novus International, Inc. ("Novus"), a consolidated subsidiary of Mitsui
Japan, against which certain actions has been filed in the San Francisco Federal
District Court by purchasers of methionine, an animal feed additive, for the
alleged violation of the U.S. antitrust laws regarding methionine, and which
settled with the class action plaintiffs in May 2002, reached an agreement for
settlement with the plaintiffs who opted out of that class action.
Under this settlement Novus will pay US$ 58 MM (approximately JY 7,100 MM) as a
settlement amount.
This will not affect Mitsui's consolidated results of operations for the fiscal
year 2003, since Novus has set up provision for the full settlement amount in
the fiscal year 2002.
Corporate Communications Div.
Mitsui & Co., Ltd.